Mereo BioPharma Q1 net loss $9.0M, cash $48.7M; setrusumab enrollment complete

Mereo BioPharma Group plc

2024-Q1 EPS reported -$0.01

Net loss $9.0M in Q1 2024 vs $12.1M in Q1 2023; operating loss $9.9M.
Cash and equivalents $48.7M as of March 31, 2024, down from $57.4M at Dec 31, 2023.
Phase 3 Orbit study (setrusumab) fully enrolled (158 patients); Cosmic enrolled 69 patients.
Alvelestat SGRQ validation completed; Phase 3 protocol to be submitted to FDA in H1 2024.
Cash guidance unchanged: funds operations into 2026; no alvelestat partnership upfront included.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.